Article Contents ::
- 1 The Brand Name INNOCYCLINE Has Generic Salt :: TIGECYCLINE
- 2 INNOCYCLINE Is From Company INNOVA LIFESCI. Priced :: Rs. 2800
- 3 INNOCYCLINE have TIGECYCLINE is comes under Sub class Miscellaneous of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name INNOCYCLINE Has Generic Salt :: TIGECYCLINE
INNOCYCLINE Is From Company INNOVA LIFESCI. Priced :: Rs. 2800
INNOCYCLINE have TIGECYCLINE is comes under Sub class Miscellaneous of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| TIGECYCLINE | Rs. 2800 | VIAL |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / VIAL |
| INNOCYCLINE | INNOVA LIFESCI. | 50MG | VIAL | Rs. 2800 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From INNOVA LIFESCI. :: INNOCYCLINE | TIGECYCLINE | Anti Infectives | Miscellaneous |
Indications for Drugs ::
Skin and Skin structure Infections: Intra-Abdominal Infections: Community-Acquired Bacterial Pneumonia
Drug Dose ::
The duration of therapy should be guided by the severity and site of the infection and the patient’s clinical and bacteriological progress. The recommended duration of treatment with Tigecycline for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days and for community-acquired bacterial pneumonia is 7 to 14 days. The recommended daily dose is as follows: Adults: The recommended dosage regimen for Tigecycline is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous (IV) infusions of Tigecycline should be administered over approximately 30 to 60 minutes every 12 hours. Pediatric use: Safety and effectiveness in pediatric patients below the age of 18 years have not been established. Geriatric use: No unexpected overall differences in safety or effectiveness were observed between these subjects and younger subjects.
Contraindication ::
Tigecycline is contraindicated for use in patients who have known hypersensitivity to Tigecycline.
Drug Precautions ::
Tigecycline is structurally similar to Tetracycline-class antibiotics and should be administered with caution in patients with known hypersensitivity to Tetracycline-class antibiotics.
Drug Side Effects ::
The most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy. The following drug-related adverse events are reported infrequently in patients receiving Tigecycline: Injection site inflammation & pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea.
Pregnancy category ::
4
Drug Mode of Action ::
A glycylcycline antibiotic that is structurally similar to tetracycline antibiotics; inhibits bacterial protein translation by binding to 30S ribosomal subunit, and blocks entry of amino-acyl tRNA molecules in ribosome A site.
Drug Interactions ::
Increased warfarin serum levels. May decrease efficacy of oral contraceptives.
